Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2970110 | 0.98 | NPC1 (0.61) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL739845 | 0.98 | NPC1 (0.61) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL19771379 | 0.85 | NPC1 (0.83) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL63450 | 0.83 | CHEK1 (0.70) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL336009 | 0.83 | NPC1 (0.65) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL4129285 | 0.82 | MAPT (0.61) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL10876210 | 0.82 | GFER (0.65) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL3159755 | 0.82 | DRD2 (0.58) | KDM4EGAAKMT2AESR2 | |
| Hydrochloric Acid SCHEMBL1222378 | 0.81 | CHEK1 (0.68) | NPC1RAB9ALMNATP53SMN1; SMN2 | |
| SCHEMBL1397464 | 0.81 | CHEK1 (0.69) | NPC1RAB9ALMNATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| CN-113646307-B | Pyrido [3,4-d ] pyrimidin-8-one derivatives having protein kinase inhibitory activity and pharmaceutical compositions thereof | 韩国科学技术研究院 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| EP-4353712-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021005583-A1 | CAMPTOTHECIN DERIVATIVES WITH A DISULFIDE MOIETY AND A PIPERAZINE MOIETY | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2021-01-14 | — | — | WO | disclosed |
| US-10336707-B2 | Heterocyclic derivatives modulating activity of certain protein kinases | EUDENDRON S.R.L. (IT) | 2019-07-02 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20180118691-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | UNVERSITA' DEGLI STUDI DI MILANO (IT) | 2018-05-03 | — | — | US | disclosed |
| WO-2008012571-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MARK INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007099166-A1 | PYRAZOLO-PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-09-07 | — | — | WO | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1487428-A4 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060052383-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1487428-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | NPC1 52/4885RAB9A 1091/4885LMNA 2866/4885 |
| US-20180118691-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | MAP4K2, MAP3K20, MAPKAPK2 | NPC1 4195/4885RAB9A 1372/4885LMNA 4551/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | NPC1 4619/4885RAB9A 1773/4885LMNA 3974/4885 |
| US-10336707-B2 | Heterocyclic derivatives modulating activity of certain protein kinases | MAP4K2, MAP3K20, MAPKAPK2 | NPC1 4195/4885RAB9A 1372/4885LMNA 4551/4885 |
| US-20060052383-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DRD4 | NPC1 2282/4885RAB9A 3215/4885LMNA 2266/4885 |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | CCNY, CCND2, CCNB1 | NPC1 4675/4885RAB9A 621/4885LMNA 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.